NCT05903430Recruiting
A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION)
A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy
Source: ClinicalTrials.gov · Last updated 5 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To determine if the investigators are able to deliver highly focused, intense radiation to tumours in the abdominal region or chest cavity whilst limiting the dose to surrounding organs using a high field strength MR-Linac.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 6 Jun 2023
- Start date
- 29 Aug 2025
- Primary completion date
- 29 Jan 2027
- Lead sponsor
- The Christie NHS Foundation Trust
- Diseases
- Lung cancer
- NCT number
- NCT05903430
What you commit to
- Study type: Observational
- Planned participants: 60
- From 29 Aug 2025 to the primary completion date, 29 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any evidence of severe or uncontrolled systemic diseases which, in the view of the investigator make it undesirable for the patient to participate in the study.
- Any patient known to have active hepatitis B, hepatitis C or human immunodeficiency virus (HIV).
Lab values
- Any evidence of significant clinical disorder or laboratory finding which, in the opinion of the investigator, make it undesirable for the patient to participate in the study.
Other
- Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form.
- Unable to tolerate MRI scans.
Who the study is looking for
- Have no MRI contra-indications.
- Eligible for abdominal SABR in accordance with the NHSE SABR Consortium Guidelines or eligible for central lung SABR in accordance with RTOG Guidelines.
- Be able to give informed consent.
- Anticipated life-expectancy \> 6 months.
- Not more than 3 oligmetastatic sites treated in total per patients.
- Performance status ≤ 2.
- Willing to attend follow-up and have details collected on prospective basis for a minimum of 1 year.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Christie NHS Foundation Trust Coordinator of this site? Confirm its status | Manchester | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.